Pharmaceutical companies argue that high prices are necessary to support innovation. Yet Commonwealth Fund President David Blumenthal, M.D., in a new Experts blog in the Wall Street Journal (subscription required), says this justification raises other questions, such as whether it’s appropriate to let the market decide how much, and how, our society spends money on research and development.
